Humana Inc. HUM is expanding its efforts to improve care delivery and manage treatment costs through a new oncology partnership with Evolent Health and American Oncology Network (AON). The collaboration introduces a cancer care model designed to improve treatment access, encourage evidence-based clinical decisions and reduce administrative hurdles for patients and providers.
The model has been launched across AON clinics in eight states. Under the arrangement, participating oncology practices that demonstrate adherence to established quality and treatment standards can bypass traditional prior authorization requirements for most anticancer drug therapies. This could help patients begin treatment sooner while reducing administrative workloads for physicians. The initiative also incorporates provider education, performance scorecards and automated electronic health record (EHR) reminders to encourage appropriate treatment decisions.
The model also relies on data analytics to support personalized cancer care. The platform, powered by Meaningful Insights Biotech Analytics (MiBA), uses real-time EHR data to generate clinical insights and guide treatment planning. By identifying patterns in clinical information, the technology could help physicians make more informed decisions, promote evidence-based treatment practices and improve care quality.
For Humana, the partnership extends its value-based care approach into complex and expensive specialty treatments. Its more than 20-year relationship with Evolent provides an established foundation for this initiative. The collaboration also broadens Humana's specialty care strategy by bringing payers, oncology providers and technology together. This integrated approach could improve care coordination, promote evidence-based treatment decisions and enhance the overall patient experience while supporting more disciplined healthcare spending.
How Are Competitors Faring?
Some of HUM’s major competitors in the value-based care space are UnitedHealth Group Incorporated UNH and Elevance Health, Inc. ELV.
Through Optum, UnitedHealth Group also offers oncology care management solutions that combine clinical guidance, evidence-based treatment pathways and provider performance incentives. UNH’s Cancer Guidance Program uses clinical reviews and technology to support appropriate treatment choices, improve care quality and manage specialty treatment expenses.
Through Carelon, Elevance Health operates an Oncology Medical Home model that combines risk-sharing arrangements, evidence-based treatment pathways and personalized patient navigation. ELV’s Cancer Care Engagement program uses predictive analytics to identify patients needing additional support, improving care coordination and helping reduce avoidable hospital admissions.
Humana’s Price Performance, Valuation & Estimates
Shares of HUM have rallied 82.2% over the past year compared with the industry’s rise of 25.6%.
Image Source: Zacks Investment Research
From a valuation standpoint, Humana trades at a forward price-to-earnings ratio of 29.08, significantly above the industry average of 15.72. HUM carries a Value Score of B.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Humana’s 2026 earnings is pegged at $9.36 per share, implying a 45.4% drop from the year-ago period.
Image Source: Zacks Investment Research
HUM stock currently flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Humana Inc. (HUM): Free Stock Analysis Report
UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report
Elevance Health, Inc. (ELV): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).